View this email in your web browser
US Autism & Asperger Association, Inc. December 10, 2008

Welcome to USAAA Weekly News, an email newsletter that addresses a range of topics on Autism Spectrum Disorders and Asperger's Syndrome.


Landmark Study: Autism recognized as medically treatable

david geier
David A. Geier, BA
mark geier
Mark Geier, MD, PhD, FABMG, FACE

WASHINGTON, DC – In April of 2008, the American College of Medical Genetics (ACMG), an AMA-recognized board, issued clinical practice guidelines that clinical geneticists should follow in determining the etiology for those with an autistic spectrum disorder (ASD) diagnosis and in treating patients with this diagnosis. This study, “Autism spectrum disorder-associated biomarkers for case evaluation and management by clinical geneticists” confirms that there are now well-established, routine, clinically available, identified biomarkers to help clinical geneticists medically evaluate and treat individuals diagnosed with an ASD and briefly outlines some recognized biomarkers.

Today, any parent, physician, or healthcare provider can easily engage the services of a clinical geneticist who is following the ACMG practice guidelines to help evaluate and treat those diagnosed with an ASD

Depending on the cause of the ASD, these researchers have found that “associated medical risks may be identified, which may lead to screening and potential morbidity prevention in patients and other family members.” The non-profit CoMeD, Inc.*, and, through a grant from the Brenen Hornstein Autism Research & Education (BHARE) Foundation, the non-profit Institute of Chronic Illnesses, Inc. funded this research study.

"Depending on the etiology [of the autism spectrum disorder], associated medical risks may be identified, which may lead to screening and potential morbidity prevention in patients and other family members."

Click here to read more.

* CoMeD, Inc. is a not-for-profit 501(c)(3) corporation that is actively engaged in legal, educational and scientific efforts to stop all use of mercury in medicine, and to ban the use of all mercury-containing medicines. Rev. Lisa K. Sykes, CoMeD President, Dr. Paul King, CoMed Scientific Advisor, David A. Geier, Vice-President, The Institute of Chronic Illnesses, Dr. Mark Geier, President, The Genetic Centers of America.


 

Act now to change health care policy
By David Berger, MD
Board Certified Pediatrician
Wholistic Pediatrics

drbergerAs America is about to undergo a significant change, and health care is one of the main parts of this change (with part of the economic stimulus package being directed towards improving the quality of medical care), this is the time to get our thoughts known. The incoming administration is currently asking for suggestions and opinions as policy is drafted. They have set up technologies to hear the ideas of individuals and groups, without the need for lobbyists.

Let the administration hear your thoughts on the need for more research into biomedical therapies and vaccine safety.

Click here to watch Senator Daschle (the leader of the health care policy transition team) talk about the personal stories that he has been reading and the ideas that have come from people’s suggestions.

Please click here and tell them your story why health care is important to you, and what you'd like to see an Obama-Biden administration do and where you'd like the country to go.

Dr. David Berger is the Medical Director for Wholistic Pediatrics in Tampa, Florida. Dr David is a Board Certified Pediatrician who specializes in holistic pediatric primary care, nutritional and detoxification therapies for autism, ADHD and related disorders and immune dysregulation.


 

Biological Plausibility of a Relationship Between Vaccines and Autism

Dr. David Berger (Dr. David), Medical Director for Wholistic Pediatrics, recently made a presentation to Florida Governor Christ’s Autism Task Force at the University of South Florida titled, "The Biological Plausibility of a Relationship Between Vaccines and Autism." Dr. David discussed immunizations, concerns about vaccines, mercury levels in fish, dental amalgams, children prone to decreased ability to detoxify, effects of oxidative stress, neurotoxicity of Thimerosal in human brain cells associated with Glutathione depletion, mitrochondria, and vaccine induced autoimmunity.

There are more children with learning disabilities and hyperinflammatory/autoimmune disorders then there has ever been in the history of medicine.

Regarding immunizations, Dr. David did not suggest that we abandon the use of vaccines, but had many concerns and said, "Are we unnaturally stressing underdeveloped immune systems beyond their capabilities in our effort to keep children from becoming ill?" He also points out that there are inadequate safety studies for the vaccines that are currently on the market.

Click here to view the entire PowerPoint presentation from Dr. David Berger presented to the Florida Autism Task Force.


 

Conflict of Interest Rampant in Child Drug Prescriptions

drugsFocus has been placed on alleged financial conflicts of interest of psychiatrists involved in the Children’s Medication Algorithm Project (CMAP). The CMAP protocol has been “quietly shelved” after objections were raised by Texas Attorney General Greg Abbott.

The state of Texas is suing a pharmaceutical company that allegedly used false advertising and improper influence to get its products on the now-mandatory adult protocol, the Texas Medication Algorithm Project (TMAP).

While pharmaceutical companies are busy paying off strategically chosen psychiatrists and Harvard experts in order to make their drugs part of lucrative state “mandatory” programs, who is looking out for the children?

Sen. Charles Grassley (R-IA) stated that three Harvard experts whose research contributed to an explosion of antipsychotic drug use in children failed to report a combined $3.2 million in company consulting fees, in violation of Harvard’s rules.

Controversy about promotion of psychotropics in children is breaking out in other states also. New Jersey state assemblyman Michael Coherty wrote to the state department of health on Aug 20, asking about the policy that permitted the NJ Medicaid program to spend $73 million between 2000 and 2007 on antipsychotic drugs for children under the age of 18 although the drugs are not FDA approved for pediatric use. Lawsuits are pending in several states.

The Dallas Morning News reported that:“At least four of CMAP"s key developers -- all affiliated with the University of Texas system, and all of them published child psychiatry experts -- have received research funding from drug companies, or have been consultants and speakers for several different pharmaceutical firms, according to their own published papers and financial disclosure forms filed with the university.

Issues include improper marketing and failure to disclose serious side effects, which prompted state programs to overpay for olanzapine (Zyprexa), quetiapine (Seroquel), and risperidone (Risperdal).

Particularly in children, it is not just the drugs prescribed, but the diagnoses that are in question. Six million children have been diagnosed with serious psychiatric disorders warranting drug treatment -- 1 million with bipolar disorder, long believed to occur only in adults.

Sadly, those who are consistently getting the short end of the stick are kids in foster care. Children in the foster care system, some as young as 3 years old, are being screened for mental illnesses and started on psychiatric drugs for disorders such as schizophrenia, bipolar disorder and depression. Among children in foster care:

• 60 percent in Texas take psychiatric drugs
• Two-thirds in Massachusetts take them
• 55 percent in Florida take the drugs

Click here to read more.




New IDEA Regulations Released by US Department of Education

On December 1, the Department of Education released new regulations for IDEA Part B that will take effect on December 31, 2008. Here's a brief summary of the major changes.

Parental Consent

If your child has been receiving special education services under IDEA and you wish to revoke consent for services:

• the revocation must be in writing, and
• the school is not required to amend your child’s education records to remove any reference to previously receiving services. §300.9(c)(3)

If parents revoke consent for services being provided to their child:

• the revocation must be in writing
• the school must provide you with written notice (under § 300.503) about their intentions for your child. This written notice may be one way of establishing just when the services should end.
• the school district may not utilize mediation or the due process procedures to challenge your revocation of consent;
• the school is not required to convene an IEP Team or develop an IEP; and
• the school will not be deemed in noncompliance with the IDEA for failure to provide a FAPE to an otherwise eligible child. §300.300(b)(4)

Click here to read more.


 

GoodSearch: You Search...We Give!Shop Online and Support USAAA

What if USAAA earned a penny every time you searched the Internet? Or how about if a percentage of every purchase you made online went to support our USAAA? Well, now it can!

GoodSearch.com is a new Yahoo-powered search engine that donates half its advertising revenue, about a penny per search, to the charities its users designate. Use it just as you would any search engine, get quality search results from Yahoo, and watch the donations add up!

GoodShop.com is a new online shopping mall which donates up to 37 percent of each purchase to USAAA! Hundreds of great stores including Amazon, Target, Gap, Best Buy, ebay, Macy's and Barnes & Noble have teamed up with GoodShop and every time you place an order, you’ll be supporting USAAA.

Just go to www.goodsearch.com and be sure to enter US Autism and Asperger Association as the charity you want to support. And, be sure to spread the word!


newsaroundtheworld


Spoof drug exposes big pharma's 'disease mongering

By Simon Palan
ABC News-Australia

drugsabcA drug company that markets sleeping pills to children in the US has received the dubious honour of taking first place in the Bad Product Awards.

Consumer advocates say the award serves to highlight what has been dubbed "disease mongering", where drug companies take everyday conditions and label them as diseases needing pharmaceutical treatment.

Disease mongering has also captured the imagination of one anti-drug company campaigner, Justine Cooper, who developed a fictitious drug, Havidol, to help illustrate the problem.

The winner of this year's [2007] international Bad Product award is a sleeping pill available in the US called Rozerem.

Consumers International says it was being promoted to children to get them through the stress of beginning a new school term.

"The ads had pictures of buses, children walking to school, chalkboards, very much insinuating imagery that was associated with schools," Mr Upchurch said.

Havidol is pushed as being for anything and everything, a make believe pill developed to parody the pharmaceutical industry.

"I created Havidol, which is a new medicine, to treat an unheard-of disorder called Dysphoric Social Attention Consumption Deficit Anxiety Disorder," she said.

Click here to read more.




GET YOUR DVDs from the
2008 USAAA International Conference
Click here to get all your conference DVDs including Holly Robinson Peete's Keynote Address
In This Issue:
Landmark Study: Autism recognized as medically treatable

Act now to change health care policy

Biological Plausibility of a Relationship Between Vaccines and Autism

Conflict of Interest Rampant in Child Drug Prescriptions

New IDEA Regulations Released by US Department of Education

Shop Online and Support USAAA

News Around the World
Spoof drug exposes big pharma's 'disease mongering

Click here for Conference DVDs





USAAA YouTube Video Channel. Be sure to subscribe to receive notices on new videos uploaded to the channel.

Click here to subscribe to the Official USAAA YouTube Video Channel. There is no cost to subscribe.


The USAAA WeeklyNews® is made possible in part by generous donations from CARE Clinics™ and Oxy Health Corporation.

Madison and Irvine Clinics

care logo
menu1
menu3
menu4
menu5
menu6
menu7
menu8




To advertise, click here.

Send us your story about your experience with autism and Asperger's Syndrome on a specific topic each week. Whether you're a parent, grandparent, caregiver, individual with autism or have any experience with autism spectrum disorders, your stories help provide insight into the world of autism.

This week's topic is: "What are your favorite Holiday recipes?"

Please send us your story in 500 words or less. Include your full name, email address, and in the subject line include this week's topic. Submissions are condensed and edited. Because of the volume of mail received, not all submissions are published. Information other than your name are kept confidential.

Click here to submit your story.

 


inbox

Inbox Readers' Comments are opinions from our subscribers. USAAA is not responsible for the content, accuracy or opinions expressed in this section.

USAAA WeeklyNews encourages readers to send guest columns for publication in our WeeklyNews. These op-eds should address timely topics of autism and Asperger's Syndrome to readers and must not exceed 600 words. Not all we receive can be published. Those that represent a well-reasoned argument, supported by evidence, in a concise and readable manner will receive priority.

Send in your comments to Inbox.



   

Disclaimer

©2008 US Autism & Asperger Association, Inc.
P.O. Box 532, Draper, UT 84020-0532
1-888-9AUTISM (1-888-928-8476) , 801-816-1234